Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para evaluar y comparar la seguridad y tolerabilidad del tratamiento de 3 meses con salbutamol administrado mediante MDI que contiene el propulsor HFA-152a o HFA-134a en participantes de 12 años o más con asma

11 de septiembre de 2026 actualizado por: GlaxoSmithKline

Un estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos para evaluar la seguridad a largo plazo del medicamento de rescate de salbutamol cuando se administra mediante inhaladores de dosis medidas que contienen el propulsor HFA-152a o el HFA-134a de referencia

The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma

Descripción general del estudio

Estado

Terminado

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Actual)

471

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Buenos Aires, Argentina, C1425BEN
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1425AZE
        • GSK Investigational Site
      • La Plata, Argentina, 1900
        • GSK Investigational Site
      • Mendoza, Argentina, M5500CCG
        • GSK Investigational Site
    • New South Wales
      • Botany, New South Wales, Australia, 2019
        • GSK Investigational Site
      • Coffs Harbour, New South Wales, Australia, 2450
        • GSK Investigational Site
      • Kanwal, New South Wales, Australia, 2259
        • GSK Investigational Site
    • Western Australia
      • Spearwood, Western Australia, Australia, 6163
        • GSK Investigational Site
    • Ontario
      • Ajax, Ontario, Canadá, L1S 2J5
        • GSK Investigational Site
      • Brampton, Ontario, Canadá, L6T 0G1
        • GSK Investigational Site
      • Ottawa, Ontario, Canadá, K1H 1E4
        • GSK Investigational Site
      • Toronto, Ontario, Canadá, M9V 4B4
        • GSK Investigational Site
      • Windsor, Ontario, Canadá, N8X 2G1
        • GSK Investigational Site
    • Quebec
      • Québec, Quebec, Canadá, G1V 4W2
        • GSK Investigational Site
      • Québec, Quebec, Canadá, G1W 4R4
        • GSK Investigational Site
      • Barcelona, España, 08017
        • GSK Investigational Site
      • Barcelona, España, 08540
        • GSK Investigational Site
      • Benalmádena, España, 29631
        • GSK Investigational Site
      • Madrid, España, 28041
        • GSK Investigational Site
      • Madrid, España, 28040
        • GSK Investigational Site
      • Madrid, España, 28031
        • GSK Investigational Site
      • Marbella, España, 29603
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, España, 28223
        • GSK Investigational Site
    • California
      • North Hollywood, California, Estados Unidos, 91606-3287
        • GSK Investigational Site
      • San Mateo, California, Estados Unidos, 94403
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, Estados Unidos, 33180
        • GSK Investigational Site
      • Clearwater, Florida, Estados Unidos, 33756
        • GSK Investigational Site
      • DeLand, Florida, Estados Unidos, 32720
        • GSK Investigational Site
      • Miami, Florida, Estados Unidos, 33173
        • GSK Investigational Site
      • Miami, Florida, Estados Unidos, 33144
        • GSK Investigational Site
      • Miami, Florida, Estados Unidos, 33155
        • GSK Investigational Site
      • Naples, Florida, Estados Unidos, 34102
        • GSK Investigational Site
      • Plantation, Florida, Estados Unidos, 33317
        • GSK Investigational Site
      • Winter Park, Florida, Estados Unidos, 32789-3385
        • GSK Investigational Site
    • Georgia
      • Rincon, Georgia, Estados Unidos, 31326-5131
        • GSK Investigational Site
      • Stonecrest, Georgia, Estados Unidos, 30038
        • GSK Investigational Site
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40217
        • GSK Investigational Site
      • Owensboro, Kentucky, Estados Unidos, 42301
        • GSK Investigational Site
    • Massachusetts
      • Fall River, Massachusetts, Estados Unidos, 02723-1511
        • GSK Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55402-2508
        • GSK Investigational Site
      • Minneota, Minnesota, Estados Unidos, 56001
        • GSK Investigational Site
    • Mississippi
      • Olive Branch, Mississippi, Estados Unidos, 38654
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, Estados Unidos, 65203
        • GSK Investigational Site
    • Nevada
      • Henderson, Nevada, Estados Unidos, 89052-5015
        • GSK Investigational Site
    • New Jersey
      • Jersey City, New Jersey, Estados Unidos, 07306
        • GSK Investigational Site
      • Riverdale, New Jersey, Estados Unidos, 07457
        • GSK Investigational Site
    • New York
      • Brooklyn, New York, Estados Unidos, 11220
        • GSK Investigational Site
    • North Carolina
      • Asheville, North Carolina, Estados Unidos, 28803
        • GSK Investigational Site
      • Winston-Salem, North Carolina, Estados Unidos, 27104
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45231
        • GSK Investigational Site
      • Dublin, Ohio, Estados Unidos, 43016
        • GSK Investigational Site
    • Oregon
      • Medford, Oregon, Estados Unidos, 97504
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, Estados Unidos, 15241
        • GSK Investigational Site
      • Pottstown, Pennsylvania, Estados Unidos, 19464-3241
        • GSK Investigational Site
    • South Carolina
      • Rock Hill, South Carolina, Estados Unidos, 29732
        • GSK Investigational Site
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • GSK Investigational Site
      • Spartanburg, South Carolina, Estados Unidos, 29303-4225
        • GSK Investigational Site
      • Union, South Carolina, Estados Unidos, 29379-7409
        • GSK Investigational Site
    • Texas
      • Sugar Land, Texas, Estados Unidos, 77479
        • GSK Investigational Site
      • Tomball, Texas, Estados Unidos, 77375-3332
        • GSK Investigational Site
      • Iloilo City, Filipinas, 5000
        • GSK Investigational Site
      • Amiens, Francia, 80054
        • GSK Investigational Site
      • Argenteuil, Francia, 95100
        • GSK Investigational Site
      • Créteil, Francia, 94010
        • GSK Investigational Site
      • Poitiers, Francia, 86021
        • GSK Investigational Site
      • Pontoise, Francia, 95303
        • GSK Investigational Site
      • Strasbourg, Francia, 67091
        • GSK Investigational Site
      • Athens, Grecia, 15669
        • GSK Investigational Site
      • Larissa, Grecia, 41110
        • GSK Investigational Site
      • Thessaloniki, Grecia, 57010
        • GSK Investigational Site
      • Cagliari, Italia, 09042
        • GSK Investigational Site
      • Florence, Italia, 50134
        • GSK Investigational Site
      • Foggia, Italia, 71100
        • GSK Investigational Site
      • Milan, Italia, 20162
        • GSK Investigational Site
      • Naples, Italia, 80131
        • GSK Investigational Site
      • Padova, Italia, 35128
        • GSK Investigational Site
      • Torino, Italia, 10128
        • GSK Investigational Site
      • Tradate VA, Italia, 21100
        • GSK Investigational Site
      • Verona, Italia, 37134
        • GSK Investigational Site
    • RM
      • Roma, RM, Italia, 00161
        • GSK Investigational Site
      • Panama City, Panamá
        • GSK Investigational Site
      • Panama City, Panamá, 7099
        • GSK Investigational Site
      • Panama City, Panamá, 7002
        • GSK Investigational Site
      • Bialystok, Polonia, 15-010
        • GSK Investigational Site
      • Bielsko-Biala, Polonia, 43-300
        • GSK Investigational Site
      • Chorzów, Polonia, 41-500
        • GSK Investigational Site
      • Elblag, Polonia, 82-300
        • GSK Investigational Site
      • Katowice, Polonia, 40-600
        • GSK Investigational Site
      • Ostrowiec Świętokrzyski, Polonia, 27-400
        • GSK Investigational Site
      • Płock, Polonia, 09-407
        • GSK Investigational Site
      • Tarnów, Polonia, 33-100
        • GSK Investigational Site
      • Bebington, Reino Unido, CH63 9JP
        • GSK Investigational Site
      • Cambridgeshire, Reino Unido, CB7 5JD
        • GSK Investigational Site
      • Corby, Reino Unido, NN17 2UR
        • GSK Investigational Site
      • Greater Manchester, Reino Unido, OL6 6HD
        • GSK Investigational Site
      • Guisborough, Reino Unido, TS14 7DJ
        • GSK Investigational Site
      • Hounslow, Reino Unido, TW3 3EL
        • GSK Investigational Site
      • Rhyl, Reino Unido, LL18 4HZ
        • GSK Investigational Site
      • Uttoxeter, Reino Unido, ST14 5JX
        • GSK Investigational Site
      • Pathum Thani, Tailandia, 12120
        • GSK Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.

  2. Asthma for ≥ 6 months, defined as:

    • Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]

    • Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:

      • Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
      • Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
      • Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
      • Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
  3. Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)

  4. Asthma Control Status

    • Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening

    • Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:

      • Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
      • An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
  5. Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.

  6. Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):

    • With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.

    • Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.

      • SABA should be withheld for ≥6 hours
      • Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
  7. Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:

    • Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.

      • SABA should be withheld for ≥6 hours
      • LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.

Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.

Exclusion Criteria:

  1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
  2. Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
  3. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
  4. Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
  5. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Salbutamol HFA-152a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 μg (ex-valve) at 30-second intervals per actuation

Comparador activo: Salbutamol HFA-134a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 microgram (μg) (ex-valve) at 30-second intervals per actuation

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Adverse Events (AEs) During Run-in Period
Periodo de tiempo: From Week -1 up to randomization (Day 1) during Run-in period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Adverse Events (AEs) During Treatment Period
Periodo de tiempo: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
Periodo de tiempo: From Week -1 up to randomization (Day 1) during Run-in period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
Periodo de tiempo: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Absolute Values of Minimum Serum Potassium
Periodo de tiempo: Up to Week 13 (Follow up)

Blood samples were collected to analyze minimum serum potassium.

Up to Week 13 (Follow up)
Absolute Values of Serum Potassium at Each Assessed Visit
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Erythrocytes
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Erythrocytes
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCV
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCH
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hematocrit
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hematocrit
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Specific Gravity
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Specific Gravity
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
Periodo de tiempo: Up to Week 13 (Follow up)

Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result.

Up to Week 13 (Follow up)
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Vital Signs: Pulse Rate
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Pulse Rate
Periodo de tiempo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
Periodo de tiempo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline for 12 Lead ECGs in QTcF
Periodo de tiempo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Heart Rate
Periodo de tiempo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Heart Rate
Periodo de tiempo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
Periodo de tiempo: Baseline (Day 1, pre-dose) and Week 12

The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Periodo de tiempo: Baseline (Day 1, pre-dose) and Week 12

Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: GSK Clinical Trials, GlaxoSmithKline

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de mayo de 2024

Finalización primaria (Actual)

2 de septiembre de 2025

Finalización del estudio (Actual)

2 de septiembre de 2025

Fechas de registro del estudio

Enviado por primera vez

8 de febrero de 2024

Primero enviado que cumplió con los criterios de control de calidad

8 de febrero de 2024

Publicado por primera vez (Actual)

15 de febrero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 220735
  • 2023-509001-76-00 (Otro identificador: EU CT Number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Marco de tiempo para compartir IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Criterios de acceso compartido de IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir